Mounjaro 5mg/0.6ml Lilly 2.4ml

Description

Mounjaro 5mg/0.6ml is a prescription only medicine indicated for:

• the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy or in addition to other medicinal products.
• weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of
  ≥ 30 kg/ m2 (obesity) or
  ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).

Mechanism of action:

Tirzepatide is a long-acting dual GIP and GLP-1 receptor agonist. Both receptors are present on the pancreatic α and β endocrine cells, heart, vasculature, immune cells (leukocytes), gut and kidney. GIP receptors are also present on adipocytes.

In addition, both GIP and GLP-1 receptors are expressed in the areas of the brain important to appetite regulation. Tirzepatide is highly selective to human GIP and GLP-1 receptors. Tirzepatide has high affinity to both the GIP and GLP-1 receptors.

Tirzepatide lowers body weight and body fat mass. The mechanisms associated with body weight and body fat mass reduction involve decreased food intake through the regulation of appetite and modulation of fat utilisation.

Contraindications:

Hypersensitivity to the active substance or to any of the excipients.

Store in a refrigerator at 2–8°C

Practitioners please note:

Additional safe guides:- when prescribing Mounjaro adults should have a BMI over 30, or those with a BMI of 27+ with at least one weight-related condition.BMI must be stated on the prescription and only x2 pens per patient per prescription. 

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions using the Yellow Card Scheme: www.mhra.gov.uk/yellowcard

EMC: https://www.medicines.org.uk/emc/product/15481/smpc#about-medicine

Patient Information Leaflet: https://www.medicines.org.uk/emc/files/pil.15481.pdf

User manual: https://www.medicines.org.uk/emc/files/usermanual.15481.pdf